Pedro Huertas, M.D., Ph.D.
Chief Medical Officer
Dr. Huertas serves as the Chief Medical Officer for Inozyme Pharma. He brings more than 30 years of experience in the pharmaceutical industry and has extensive experience in research and development and medical and regulatory affairs, especially regarding rare disorders and enzyme replacement therapies.
He recently was the Chief Medical Officer at Sentien Pharmaceuticals and before that held the same position at Eloxx Pharmaceuticals. In addition, Dr. Huertas has worked for leading orphan drug developers such as Genzyme, Shire and Amicus and has experience working with small molecules, biologics and cellular therapies across multiple therapeutic categories, including cardiology, nephrology, hematology and ophthalmology.
Dr. Huertas trained at Massachusetts General Hospital and holds several advanced degrees, including an MD from Harvard Medical School, a PhD in cell and developmental biology from Harvard University, an MS in biochemistry from Stanford University, and an MS in management from the Sloan School of Management at the Massachusetts Institute of Technology.